Archive

Archive for the ‘Sector Analysis’ Category

Targeting Ischemic Diseases by Improving Blood Flow, Cytori Therapeutics (CYTX)

July 21st, 2010 Henry McCusker No comments

A new analyst review of Cytori Therapeutics. (NASDAQ:CYTX) entitled, “Targeting Ischemic Diseases   by Improving Blood Flow.” Read more…

Update on Clinical Safety Data, Neuralstem, Inc. (NYSE Amex: CUR)

May 25th, 2010 Henry McCusker No comments

CUR updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig’s disease) at Emory University in Atlanta, Georgia. Read more…

Scimitar Equity Issues Q3/10 Analyst Review for Aastrom Biosciences (ASTM)

May 13th, 2010 Henry McCusker No comments

Scimitar Equity, LLC has issued a review of Aastrom Biosciences, Inc. (NASDAQ:ASTM) entitled, “Three (3) Late Stage Trials Focus the Future Stock Appreciation”.  Scimitar Equity maintains a BUY ranking.   This review is available at website: ASTM Q3/10 Review Read more…

Three (3) Stem Cell Lines Now on Hold by the NIH

May 5th, 2010 Henry McCusker No comments

Three (3) human embryonic stem cell lines once eligible (5/4/10) for federal funding are “on hold” until further notice because they were derived from embryos that were too early. “These lines were derived from early embryos — those consisting of 6, 8, or 16 cells and thus formally did not fit the official definition of ES cells by the NIH,” Read more…

NIH Study Confirms Location of Stem Cells Near Cartilage

May 4th, 2010 Henry McCusker No comments

NIH Researchers have discovered bone-generating stem cells in the spine, at the end of the shins and in cartilage-rich areas of other bones. They also identified factors that control the growth of these stem cells, according to a report published (4/26/10) in the Proceedings of the National Academy of Sciences. The potential for this market is HUGE and will continue to grow as the population ages and minimally invasive surgeries and shorter hospital stays become a new standard. Read more…

New NIH Common Fund

February 27th, 2010 Henry McCusker No comments

 Programs to create a new center for the study of stem cells and to increase capacity to deal with global health issues were among 7 scientific initiatives announced 2/25/10 by NIH Director Francis S. Collins, MD, PhD. The 7 research programs are supported through the NIH Common Fund, which encourages collaborative research programs across the NIH institutes and centers (IC) to accomplish work that no single IC could do alone. Read more…

Q4/09 Results, Osiris Therapeutics (OSIR)

February 25th, 2010 Henry McCusker No comments

Osiris Therapeutics is a stem cell therapeutic company focused on developing products in the inflammatory, orthopedic and cardiovascular areas.  OSIR’s  Q4/09 results reported achievement and data showing Prochymal achieved a 63% response rate when used as a rescue agent in children with end-stage GvHD with significant improvement in response rates over standard of care for both liver and gastrointestinal steroid-refractory GvHD – the two most deadly and difficult-to-treat forms of the disease.  Graft-versus-host disease (GvHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as “foreign” and mount an immunologic attack.

Read more…

Updating, BrainStorm Cell Therapeutics (OTCBB: BCLI)

February 24th, 2010 Henry McCusker No comments

BCLI.OB announced that it has entered into agreements with 3 investors with each investing $500 K for a total of investment of $1.5 M with issuance to each of 3 investors,  2 M shares of stock based on the 30 day average share price as of 2/11/10 of $0.25 per share and 1 M warrants with an exercise price of $0.50 per share for a total issuance of 6 M shares and 3 M warrants.  Read more…

Follow-Up Info, Advanced Cell Technology, Inc. (NASDAQ: ACTC.OB),

February 24th, 2010 Henry McCusker No comments

The objective of the filed IND Application is to start a Phase I/II study at multiple centers. The study would involve the use of retinal cells, which have been developed from the stem cells of the embryo for the treatment of patients suffering Stargardt’s Macular Dystrophy (SMD).

Read more…

One-for-Eight Reverse Stock Split Effective, Aastrom (ASTMD)

February 18th, 2010 Henry McCusker No comments

The resulting effect of the reverse stock split is that every 8 shares of the issued/outstanding common stock prior to the opening of trading will be combined into 1 issued without any change in the par value of shares with the number of authorized but unissued shares of the common stock proportionally reduced. As a result, ASTM (D) could have approximately (rough calculation) 30 M shares outstanding with a total fully diluted value of 40 M including warrants and options.

Read more…